A tenet of drug discovery states that molecules greater than a certain size don't enter cells. But not only do certain synthetic peptides refute this idea, they also inhibit 'undruggable' biological targets.
This is a preview of subscription content, log in via an institution to check access.
References
Moellering, R. E. et al. Nature 462, 182–188 (2009).
Wells, J. A. & McClendon, C. L. Nature 450, 1001–1009 (2007).
Jones, S. & Thornton, J. M. Proc. Natl Acad. Sci. USA 93, 13–20 (1996).
Mapp, A. K. & Ansari, A. Z. ACS Chem. Biol. 2, 62–75 (2007).
Schafmeister, C. E., Po, J. & Verdine, G. L. J. Am. Chem. Soc. 122, 5891–5892 (2000).
Henchey, L. K., Jochim, A. L. & Arora, P. S. Curr. Opin. Chem. Biol. 12, 692–697 (2008).
Wender, P. A. et al. Proc. Natl Acad. Sci. USA 97, 13003–13008 (2000).
Walensky, L. D. et al. Science 305, 1466–1470 (2004).
Darnell, J. E. Jr Nature Rev. Cancer 2, 740–749 (2002).
Vazquez, A., Bond, E. E., Levine, A. J. & Bond, G. L. Nature Rev. Drug Discov. 7, 979–987 (2008).
Oh, W. J., Rishi, V., Orosz, A., Gerdes, M. J. & Vinson, C. Cancer Res. 67, 1867–1876 (2007).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Arora, P., Ansari, A. A Notch above other inhibitors. Nature 462, 171–173 (2009). https://doi.org/10.1038/462171a
Published:
Issue Date:
DOI: https://doi.org/10.1038/462171a
- Springer Nature Limited
This article is cited by
-
Versatile synthesis of fluorescent, cross-linked peptides as biological probes with the advantage of high helix content
Research on Chemical Intermediates (2013)
-
Antiviral activity of α-helical stapled peptides designed from the HIV-1 capsid dimerization domain
Retrovirology (2011)
-
Trastuzumab and beyond: sequencing cancer genomes and predicting molecular networks
The Pharmacogenomics Journal (2011)